

Special Issue

Recent Advances in Rare Cancers: From Bench to Bedside and Back

Message from the Guest Editor

About one in eight cancers diagnosed in adults belongs to the group of Rare Cancers, which by common definition occur at an annual incidence of less than 6 cases per 100,000 of the population. This group encompasses a very large and heterogeneous range of cancers including carcinomas, sarcomas, and neuronal and hematologic malignancies. Increasing identification and definition of subtypes of these rare tumors fosters an understanding of their biologic dimensions. For instance, soft tissue sarcomas, a Rare Cancer occurring at an incidence of less than 5 per 100,000 of the population, may be subclassified into more than 70 subtypes with different biologies, clinical behaviors, and treatments. The downside of the identification of increasingly scarce subtypes of Rare Cancers is that classical clinical drug development via randomized clinical trials may become futile, owing to the impossibility of enrolling sufficient patient numbers. This back-to-back Special Issue of *Cancers* provides a platform for latest research into Rare Cancers, showcasing new insights into their management.

Guest Editor

Prof. Dr. Wolfgang Johannes Köstler

Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

Deadline for manuscript submissions

closed (20 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/169190

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)